{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:38:05Z","timestamp":1787017085714,"version":"build-2736575974"},"reference-count":43,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Following administration of chimeric antigen receptor (CAR) T-cell therapy, extensive long-term follow-up (LTFU) requirements and complex data collection processes have posed significant challenges for patients and providers. To reassess whether a 15-year LTFU period remains scientifically justified, we convened a multistakeholder working group that included representatives from patient advocacy groups, academia, industry, and government. This analysis incorporates newly aggregated primary data on composite percentages of adverse events (AEs) reported by year for five Food and Drug Administration-approved CAR T-cell therapies. Combined with previously published research, the findings indicate that AEs are infrequently reported after 3 years post-infusion, and secondary T-cell malignancy\u2014the AE of primary concern based on the mechanism of action of CAR T-cell therapy\u2014has predominantly been reported within the first 2 years. Based on current cumulative safety data, a 5-year follow-up period may be scientifically sufficient in both clinical trial and commercial settings. Additionally, we propose a streamlined process that leverages technological advancements to automate the transfer of focused safety data from electronic health records into a third-party database. To facilitate implementation, we recommend feasibility testing of this updated data collection approach using an established platform. We also outline regulatory policy considerations to most effectively enable adoption of these recommendations.<\/jats:p>","DOI":"10.1136\/jitc-2025-013878","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:40:14Z","timestamp":1776130814000},"page":"e013878","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Data-informed optimization of CAR T-cell therapy long-term follow-up"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-250X","authenticated-orcid":false,"given":"Betsy","family":"Foss-Campbell","sequence":"first","affiliation":[{"name":"Catalyst Healthcare Consulting Inc, McLean, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Myers","sequence":"additional","affiliation":[{"name":"Catalyst Healthcare Consulting Inc, McLean, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Awasthi","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Bechtle","sequence":"additional","affiliation":[{"name":"J&J, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette","family":"Boerstoel Streefland","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Corbett","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Dewees","sequence":"additional","affiliation":[{"name":"Artiva Biotherapeutics Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Eastwood","sequence":"additional","affiliation":[{"name":"Emily Whitehead Foundation, Philipsburg, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Jadlowsky","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Joy","family":"Martin","sequence":"additional","affiliation":[{"name":"Kite Pharma Inc, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Langeberg","sequence":"additional","affiliation":[{"name":"A2 Biotherapeutics Inc, Agoura Hills, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Lee","sequence":"additional","affiliation":[{"name":"J&J, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Marshall","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen","family":"Nichols","sequence":"additional","affiliation":[{"name":"Blood Cancer United, Rye Brook, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Shiu","sequence":"additional","affiliation":[{"name":"Kite Pharma Inc, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-0736","authenticated-orcid":false,"given":"Mark","family":"Stewart","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P","family":"Tschernia","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Willert","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Xu","sequence":"additional","affiliation":[{"name":"Kite Pharma Inc, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H","family":"June","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2026041318400603000_14.4.e013878.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2026041318400603000_14.4.e013878.2","unstructured":"US. Food and Drug Administration . FDA investigating serious risk of t-cell malignancy following bcma- or cd19-directed autologous car t cell immunotherapies. 2024. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous"},{"key":"2026041318400603000_14.4.e013878.3","unstructured":"U.S. Food and Drug Administration . Long term follow-up after administration of human gene therapy products: guidance for industry. Silver Spring (MD): Center for Biologics Evaluation and Research; 2020. Available: https:\/\/www.fda.gov\/media\/113768\/download"},{"key":"2026041318400603000_14.4.e013878.4","unstructured":"Myers NB , Serman T , Foss-Campbell B , et al . Amplifying the voice of car t-cell therapy patients and caregivers: survey results to better understand patient experiences with long-term follow-up studies. Emily Whitehead Foundation. 2024 Available: https:\/\/www.catalysthcc.com\/insights-news-blog\/catalyst-in-collaboration-with-the-emily-whitehead-foundation-publishes-amplifying-the-voice-of-car-t-cell-therapy-patients-and-caregivers"},{"key":"2026041318400603000_14.4.e013878.5","unstructured":"Bringing car t-cell therapies to community oncology. n.d. Available: https:\/\/www.accc-cancer.org\/education-and-resources\/clinical-practice-treatment\/treatment\/immunotherapy\/car-t-cell-therapy\/bringing-car-t-cell-therapies-to-community-oncology"},{"key":"2026041318400603000_14.4.e013878.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03478-6"},{"key":"2026041318400603000_14.4.e013878.7","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1182\/bloodadvances.2022008093","article-title":"Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy","volume":"6","author":"Hsieh","year":"2022","journal-title":"Blood Adv"},{"key":"2026041318400603000_14.4.e013878.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02767-w"},{"key":"2026041318400603000_14.4.e013878.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209"},{"key":"2026041318400603000_14.4.e013878.10","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1016\/j.ymthe.2025.08.043","article-title":"Isolated oral CD30(+)\/CD4(+) CAR(+) T cell lymphoma in long-term remission after radiotherapy","volume":"33","author":"Bezerra","year":"2025","journal-title":"Mol Ther"},{"key":"2026041318400603000_14.4.e013878.11","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/bloodadvances.2023012336","article-title":"Answering the \u201cDoctor, can CAR-T therapy cause cancer?\u201d question in clinic","volume":"8","author":"Banerjee","year":"2024","journal-title":"Blood Adv"},{"key":"2026041318400603000_14.4.e013878.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402730"},{"key":"2026041318400603000_14.4.e013878.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361"},{"key":"2026041318400603000_14.4.e013878.14","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"key":"2026041318400603000_14.4.e013878.15","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"2026041318400603000_14.4.e013878.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"2026041318400603000_14.4.e013878.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"2026041318400603000_14.4.e013878.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02826-w"},{"key":"2026041318400603000_14.4.e013878.19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"2026041318400603000_14.4.e013878.20","doi-asserted-by":"crossref","unstructured":"Thieblemont C , Dreyling M , Dickinson MJ , et al . Clinical Outcomes of Patients with High-Risk Relapsed\/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update. Blood 2024;144. doi:10.1182\/blood-2024-201730","DOI":"10.1182\/blood-2024-201730"},{"key":"2026041318400603000_14.4.e013878.21","doi-asserted-by":"crossref","unstructured":"John S , Curran KJ , Hall EM , et al . Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Advances. 2025. doi:10.1182\/bloodadvances.2025015881","DOI":"10.1182\/bloodadvances.2025015881"},{"key":"2026041318400603000_14.4.e013878.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00642"},{"key":"2026041318400603000_14.4.e013878.23","doi-asserted-by":"crossref","first-page":"107042","DOI":"10.1016\/j.leukres.2023.107042","article-title":"Incidence of second primary malignancies in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma patients in England","volume":"127","author":"Miret","year":"2023","journal-title":"Leukemia Research"},{"key":"2026041318400603000_14.4.e013878.24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2018.01.006","article-title":"Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents","volume":"24","author":"Sahebi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041318400603000_14.4.e013878.25","doi-asserted-by":"crossref","unstructured":"Tix T , Alhomoud M , Shouval R , et al . Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients. Clin Cancer Res 2024;30. doi:10.1016\/j.bbmt.2018.01.006","DOI":"10.1158\/1078-0432.c.7494018"},{"key":"2026041318400603000_14.4.e013878.26","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/bloodadvances.2021006369","article-title":"Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study","volume":"6","author":"Joelsson","year":"2022","journal-title":"Blood Adv"},{"key":"2026041318400603000_14.4.e013878.27","doi-asserted-by":"crossref","unstructured":"Gazeau N , Beauvais D , Tilmont R , et al . Myeloid Neoplasia after CD19 Directed CAR-T Cells: Cumulative Incidence, Risk Factors and Outcome. Blood 2024;144.doi:10.1182\/blood-2024-208851.","DOI":"10.1182\/blood-2024-208851"},{"key":"2026041318400603000_14.4.e013878.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02529-x"},{"key":"2026041318400603000_14.4.e013878.29","unstructured":"American Cancer Society . Treating b-cell non-hodgkin lymphoma. 2025. Available: https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/treating\/b-cell-lymphoma.html"},{"key":"2026041318400603000_14.4.e013878.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"2026041318400603000_14.4.e013878.31","unstructured":"U.S. Food and Drug Administration . Gene therapy clinical trials \u2013 observing subjects for delayed adverse events: guidance for industry. U.S. Department of Health and Human Services, Center for Biologics Evaluation and Research; 2006. Available: https:\/\/www.govinfo.gov\/content\/pkg\/GOVPUB-HE20_4000-PURL-LPS112486\/pdf\/GOVPUB-HE20_4000-PURL-LPS112486.pdf"},{"key":"2026041318400603000_14.4.e013878.32","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0234-5"},{"key":"2026041318400603000_14.4.e013878.33","unstructured":"U.S. Food and Drug Administration . Real-world evidence submissions to the center for biologics evaluation and research. 2025. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/real-world-evidence-submissions-center-biologics-evaluation-and-research"},{"key":"2026041318400603000_14.4.e013878.34","unstructured":"Tiech\u00e9 MB . What are the most common inpatient ehr systems. Definitive Healthcare; 2024. Available: https:\/\/www.definitivehc.com\/blog\/most-common-inpatient-ehr-systems"},{"key":"2026041318400603000_14.4.e013878.35","unstructured":"Chang W , Gabriel MH , Everson J . TEFCA awareness and planned participation among U.S. hospitals: 2023. 2024;Available from:72."},{"key":"2026041318400603000_14.4.e013878.36","unstructured":"Office of the National Coordinator for Health Information Technology . What is FHIR?. Washington (DC): ONC; 2019. Available: https:\/\/www.healthit.gov\/sites\/default\/files\/2019-08\/ONCFHIRFSWhatIsFHIR.pdf"},{"key":"2026041318400603000_14.4.e013878.37","unstructured":"Office of the National Coordinator for Health Information Technology . United states core data for interoperability (USCDI). Washington (DC): ONC; 2025. Available: https:\/\/www.healthit.gov\/isp\/united-states-core-data-interoperability-uscdi"},{"key":"2026041318400603000_14.4.e013878.38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtct.2023.06.014","article-title":"Cell Therapy Informatics: Updates on the Integration of HCT\/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability","volume":"29","author":"Ho","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026041318400603000_14.4.e013878.39","unstructured":"Ezzeldin H . Enhancing biologics adverse event surveillance via scalable, fhir-based infrastructure: how does the fda use real world data and real-world evidence. Nashville, TN Conference Presentation on the Internet]. In: AABB Annual Meeting. Available: https:\/\/bestinitiative.org\/wp-content\/uploads\/2024\/02\/AABB-Annual-Meeting-Presentation.-2023-Oct-14-17.pdf"},{"key":"2026041318400603000_14.4.e013878.40","unstructured":"Ezzeldin H . Enhancing biologics adverse event surveillance via scalable,FHIR-based infrastructure: how does the fda use real world data and real-world evidence. conference presentation on the Internet]. In: eHealth Exchange Annual Meeting; 2023. Available: https:\/\/bestinitiative.org\/wp-content\/uploads\/2024\/02\/eHealth-Exchange-Annual-Meeting-Presentation.-2023-Nov-14.pdf"},{"key":"2026041318400603000_14.4.e013878.41","unstructured":"U.S. Department of Health and Human Services . Standards for privacy of individually identifiable health information, 45 C.F.R \u00a7\u00a7 164.502, 164.514. 2000. Available: https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-C\/part-164\/subpart-E"},{"key":"2026041318400603000_14.4.e013878.42","unstructured":"U.S. Food and Drug Administration . Considerations for the use of artificial intelligence to support regulatory decision making for drug and biological products. Silver Spring (MD): FDA; 2025. Available: https:\/\/www.fda.gov\/media\/184830\/download"},{"key":"2026041318400603000_14.4.e013878.43","unstructured":"U.S. Food and Drug Administration . Approved cellular and gene therapy products. 2025. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:40:25Z","timestamp":1776130825000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,13]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/jitc-2025-013878"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013878","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}